The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment
Rahul Banerjee, MD, FACP, discusses how the emergence of CAR T-cell therapy has impacted the multiple myeloma treatment landscape by addressing unmet needs and improving patients’ quality of life.
EP: 1.The Rationale for CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Now Viewing
EP: 2.The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment
EP: 3.How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment
EP: 4.Key Takeaways from the CARTITUDE-1 and KarMMa Studies
EP: 5.CAR T-Cell Therapy in R/R MM: Treatment Selection, Safety, and Future Perspectives
EP: 6.Insights from CARTITUDE-4 and KarMMa-3 in R/R MM
EP: 7.Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM
Video content above is prompted by the following questions:
- How has the emergence of CAR T-cell therapy impacted the treatment paradigm for relapsed/refractory multiple myeloma?
- Does this therapy address an unmet need in R/R MM?
- How do you manage patients who may not meet the eligibility criteria for CAR T-cell therapy but still have a significant unmet need for effective treatment options?
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
